BioNTech SE (BNTX) Reports Q2 EPS of EUR6.45
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
BioNTech SE (BNTX) Slides on Vaccine Revenue Miss But Consensus Was 'Too High'
August 8, 2022 3:32 PM EDTBioNTech SE (NASDAQ: BNTX) shares tumbled more than 9% Monday after reporting second-quarter earnings before the open.
The drugmaker posted second-quarter earnings of 6.45 per share on revenue of 3.2 billion. Earnings and revenue fell from the second quarter of 2021, where it reported a profit of 10.77 per share on revenue of $5.3 billion.
"With our strong performance year to date, we believe to be well on track to achieve our previous financial guidance for the ongoing financial year,"... More
